US-based drug-development services company Aptuit has completed its senior management team by enlisting Dr Jonathan Goldman from ICON Clinical Research as chief executive officer (CEO).
The new appointment was announced by Aptuit chairman Timothy Tyson, who served as the company’s CEO from 2008 to 2012. Dr Goldman had been executive vice president, global strategic and business development at ICON Clinical Research since December 2010.
He will focus on driving growth at Aptuit as a leading provider of outsourced services in the early development space, by establishing new partnerships with clients and pursuing strategic acquisitions, the company said.
ICON legacy
Goldman joined ICON Clinical Research in April 2010 to head up the division’s Strategic Programs group, with responsibility for strategic relationships and management of external alliances.
Previous roles at ICON, the global provider of outsourced drug-development services based in Ireland, included executive vice president, operations and chief medical officer, ICON Medical Imaging.
Before that, Goldman served for seven years as chief medical officer of POINT Biomedical, a US-based biopharmaceutical company focused on microsphere technologies and drugs.
According to Tyson, Goldman brings to Aptuit “exceptional experience in science, sales and medicine, along with the innate talents that are needed to advance us to the next level of growth and accomplishments”.
